An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.
By Pooja Toshniwal Paharia Researchers discover that COVID-19 mRNA vaccines do not generate long-lasting plasma cells in the ...
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403: Cambridge, Massachusetts Thursday, October 3, 2024, 12:00 Hrs [IST] Moderna, Inc, a global l ...
Engineers have discovered a simple and inexpensive means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, ...
截至2024年9月30日 11:03,中证疫苗与生物技术指数强势上涨9.99%,成分股智飞生物上涨17.04%,沃森生物上涨16.38%,纳微科技上涨15.66%,康希诺、康华生物等个股跟涨。疫苗ETF(562860)涨停,冲击5连涨。拉长时间看,截 ...
During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA ...
在新冠疫情激发全球疫苗研发热潮的背景下,mRNA技术凭借其灵活性和高效性,逐渐走入公众视野。最近,中信证券发布的研报指出,2025年可能成为mRNA肿瘤疫苗的商业化元年。这个消息无疑引发了市场的广泛关注与期待。这种突破性的医学技术将在癌症治疗领域掀起怎样的波澜?本文将深入探讨mRNA肿瘤疫苗的市场前景与未来发展。
2021年8月3日,赛诺菲宣布与临床阶段mRNA治疗药物公司Translate Bio(纳斯达克股票代码:TBIO)达成了一项最终协议(definitive agreement),赛诺菲将以每股38美元收购Translate ...
While using mRNA as medicine is new, mRNA has been inside you for your entire life. The cells in your body create mRNAs that serve as instructions to make specific proteins you need to function.